Microvascular thrombosis: An exciting but elusive therapeutic target in reperfused acute myocardial infarction

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 10, Issue 4, 2010, Pages 273-283

  Barrabés, José A ^a   Inserte, Javier ^a   Agulló, Luis ^a   Alonso, Albert ^a   Mirabet, Maribel ^a   Garcia Dorado, David ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Acute myocardial infarction; Antithrombotic agents; Ischemia; Microcirculation; Platelets; Reperfusion

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE; ANTITHROMBOCYTIC AGENT; CANGRELOR; CLOPIDOGREL; FIBRINOGEN RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICORANDIL; NITROPRUSSIDE SODIUM; PURINERGIC P2Y12 RECEPTOR; THIENOPYRIDINE DERIVATIVE;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ARTICLE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HUMAN; MICROVASCULATURE; NONHUMAN; THROMBOCYTE; THROMBOCYTE ACTIVATION; VASOCONSTRICTION;

EID: 79953885791     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152910793743797     Document Type: Article

References (107)

1. Heidenreich, P.A.; McClellan, M. Trends in treatment and outcomes for acute myocardial infarction: 1975-1995. Am. J. Med., 2001, 110, 165-174.
2. Boersma, E.; Maas, A.C.; Deckers, J.W.; Simoons, M.L. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet, 1996, 348, 771-775.
3. Gersh, B.J.; Stone, G.W.; White, H.D.; Holmes, D.R.; Jr. Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: is the slope of the curve the shape of the future? JAMA, 2005, 293, 979-986.
4. Rezkalla, S.H.; Kloner, R.A. Coronary no-reflow phenomenon: from the experimental laboratory to the cardiac catheterization laboratory. Catheter. Cardiovasc. Interv., 2008, 72, 950-957.
5. Ito, H. No-reflow phenomenon and prognosis in patients with acute myocardial infarction. Nat. Clin. Pract. Cardiovasc. Med., 2006, 3, 499-506.
6. Barrabés, J.A.; Barba, I. Medium-term changes in myocardial perfusion and ventricular remodeling following acute myocardial infarction. Rev. Esp. Cardiol., 2007, 60, 468-470.
7. Reffelmann, T.; Hale, S.L.; Dow, J.S.; Kloner, R.A. No-reflow phenomenon persists long-term after ischemia/reperfusion in the rat and predicts infarct expansion. Circulation, 2003, 108, 2911-2917.
8. Bolognese, L.; Carrabba, N.; Parodi, G.; Santoro, G.M.; Buonamici, P.; Cerisano, G.; Antoniucci, D. Impact of microvascular dysfunction on left ventricular remodeling and long-term clinical outcome after primary coronary angioplasty for acute myocardial infarction. Circulation, 2004, 109, 1121-1126.
9. Kloner, R.A.; Ganote, C.E.; Jennings, R.B. The no-reflow phenomenon after temporary coronary occlusion in the dog. J. Clin. Invest., 1974, 54, 1496-1508.
10. Garcia-Dorado, D.; Théroux, P.; Solares, J.; Alonso, J.; Fernandez-Avilés, F.; Elizaga, J.; Soriano, J.; Botas, J.; Munoz, R. Determinants of hemorrhagic infarcts: histologic observations from experiments involving coronary occlusion, coronary reperfusion, and reocclusion. Am. J. Pathol., 1990, 137, 301-311.
11. García-Dorado, D.; Oliveras, J.; Gili, J.; Sanz, E.; Pérez-Villa, F.; Barrabés, J.; Carreras, M.J.; Solares, J.; Soler-Soler, J. Analysis of myocardial oedema by magnetic resonance imaging early after coronary artery occlusion with or without reperfusion. Cardiovasc. Res. 1993, 27, 1462-1469 [Erratum in: Cardiovasc. Res. 1993, 27, 1889].
12. Garcia-Dorado, D.; Oliveras, J. Myocardial oedema: a preventable cause of reperfusion injury? Cardiovasc. Res., 1993, 27, 1555-1563.
13. Sanz, E.; García Dorado, D.; Oliveras, J.; Barrabés, J.A.; Gonzalez, M.A.; Ruiz-Meana, M.; Solares, J.; Carreras, M.J.; García-Lafuente, A.; Desco, M.; Soler-Soler, J. Dissociation between antiinfarct effect and anti-edema effect of ischemic preconditioning. Am. J. Physiol., 1995, 268, H233-H241.
14. Barrabés, J.A.; Garcia-Dorado, D.; Soriano, B.; Solares, J.; Puigfel, Y.; Trobo, L.; Garcia-Lafuente, A.; Soler-Soler, J. Dynamic intracoronary thrombosis does not cause significant downstream platelet embolization. Cardiovasc. Res., 2000, 47, 265-273.
15. Frangogiannis, N.G.; Smith, C.W.; Entman, M.L. The inflammatory response in myocardial infarction. Cardiovasc. Res., 2002, 53, 31-47.
16. Bekkers, S.C.; Yazdani, S.K.; Virmani, R.; Waltenberger, J. Microvascular obstruction: underlying pathophysiology and clinical diagnosis. J. Am. Coll. Cardiol., 2010, 55, 1649-1660.
17. Kloner, R.A.; Rude, R.E.; Carlson, N.; Maroko, P.R.; DeBoer, L.W.; Braunwald, E. Ultrastructural evidence of microvascular damage and myocardial cell injury after coronary artery occlusion: which comes first? Circulation, 1980, 62, 945-952.
18. Ault, K.A.; Cannon, C.P.; Mitchell, J.; McCahan, J.; Tracy, R.P.; Novotny, W.F.; Reimann, J.D.; Braunwald, E. Platelet activation in patients after an acute coronary syndrome: results from the TIMI 12 trial. Thrombolysis in Myocardial Infarction. J. Am. Coll Cardiol., 1999, 33, 634-639.
19. Mathur, A.; Robinson, M.S.C.; Cotton, J.; Martin, J.F.; Erusalimsky, J.D. Platelet reactivity in acute coronary syndromes: evidence for differences in platelet behaviour between unstable angina and myocardial infarction. Thromb. Haemost., 2001, 85, 989-994.
20. Michelson, A.D.; Barnard, M.R.; Krueger, L.A.; Valeri, C.R.; Furman, M.I. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation, 2001, 104, 1533-1537.
21. Frossard, M.; Fuchs, I.; Leitner, J.M.; Hsieh, K.; Vlcek, M.; Losert, H.; Domanovits, H.; Schreiber, W.; Laggner, A.N.; Jilma, B. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation, 2004, 110, 1392-1397.
22. Nordt, T.K.; Moser, M.; Kohler, B.; Ruef, J.; Peter, K.; Kübler, W.; Bode, C. Augmented platelet aggregation as predictor of reocclusion after thrombolysis in acute myocardial infarction. Thromb. Haemost. 1998, 80, 881-886.
23. Fuchs, I.; Frossard, M.; Spiel, A.; Riedmüller, E.; Laggner, A.N.; Jilma, B. Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS. J. Thromb. Haemost., 2006, 4, 2547-2552.
24. Niccoli, G.; Giubilato, S.; Russo, E.; Spaziani, C.; Leo, A.; Porto, I.; Leone, A.M.; Burzotta, F.; Riondino, S.; Pulcinelli, F.; Biasucci, L.M.; Crea, F. Plasma levels of thromboxane A2 on admission are associated with no-reflow after primary percutaneous coronary intervention. Eur. Heart J., 2008, 29, 1843-1850.
25. Mirabet, M.; Garcia-Dorado, D.; Inserte, J.; Barrabés, J.A.; Lidón, R.M.; Soriano, B.; Azevedo, M.; Padilla, F.; Agulló, L.; Ruiz-Meana, M.; Massaguer, A.; Pizcueta, P.; Soler-Soler, J. Platelets activated by transient coronary occlusion exacerbate ischemiareperfusion injury in rat hearts. Am. J. Physiol. Heart Circ. Physiol., 2002, 283, H1134-H1141.
26. Barrabés, J.A.; Mirabet, M.; Agulló, L.; Figueras, J.; Pizcueta, P.; Garcia-Dorado, D. Platelet deposition in remote cardiac regions after coronary occlusion. Eur. J. Clin. Invest., 2007, 37, 939-946.
27. Xu, Y.; Huo, Y.; Toufektsian, M.C.; Ramos, S.I.; Ma, Y.; Tejani, A.D.; French, B.A.; Yang, Z. Activated platelets contribute importantly to myocardial reperfusion injury. Am. J. Physiol. Heart Circ. Physiol., 2006, 290, H692-H699.
28. Romson, J.L.; Hook, B.G.; Rigot, V.H.; Schork, M.A.; Swanson, D.P.; Lucchesi, B.R. The effect of ibuprofen on accumulation of indium-111-labeled platelets and leukocytes in experimental myocardial infarction. Circulation, 1982, 66, 1002-1011.
29. Feinberg, H.; Rosenbaum, D.S.; Levitsky, S.; Silverman, N.A.; Kohler, J.; LeBreton, G. Platelet deposition after surgically induced myocardial ischemia: an etiologic factor for reperfusion injury. J. Thorac. Cardiovasc. Surg., 1982, 84, 815-822.
30. Laws, K.H.; Clanton, J.A.; Starnes, V.A.; Lupinetti, F.M.; Collins, J.C.; Oates, J.A.; Hammon, J.W.; Jr. Kinetics and imaging of indium-111-labeled autologous platelets in experimental myocardial infarction. Circulation, 1983, 67, 110-116.
31. Bednar, M.; Smith, B.; Pinto, A.; Mullane, K.M. Neutrophil depletion suppresses 111In-labeled platelet accumulation in infracted myocardium. J. Cardiovasc. Pharmacol., 1985, 7, 906-912.
32. Libersan, D.; Quan, E.; Merhi, Y.; Uzan, A.; Laperrière, L.; Latour, J.G. Intravenous aspirin at reperfusion does not reduce infarct size in the dog with a residual critical stenosis. J. Cardiovasc. Pharmacol., 1999, 34, 575-583.
33. Barrabés, J.A.; Garcia-Dorado, D.; Mirabet, M.; Lidón, R.M.; Soriano, B.; Ruiz-Meana, M.; Pizcueta, P.; Blanco, J.; Puigfel, Y.; Soler-Soler, J. Lack of effect of glycoprotein IIb/IIIa blockade on myocardial platelet or polymorphonuclear leukocyte accumulation and on infarct size after transient coronary occlusion in pigs. J. Am. Coll. Cardiol., 2002, 39, 157-165.
34. Barrabés, J.A.; Garcia-Dorado, D.; Mirabet, M.; Inserte, J.; Agulló, L.; Soriano, B.; Massaguer, A.; Padilla, F.; Lidón, R.M.; Soler-Soler, J. Antagonism of selectin function attenuates microvascular platelet deposition and platelet-mediated myocardial injury after transient ischemia. J. Am. Coll. Cardiol., 2005, 45, 293-299.
35. Jørgensen, L.; Hovig, T.; Rowsell, H.C.; Mustard, J.F. Adenosine diphosphate-induced platelet aggregation and vascular injury in swine and rabbits. Am. J. Pathol., 1970, 61, 161-176.
36. Rösen, R.; Dausch, W.; Beck, E.; Klaus, W. Platelet induced aggravation of acute ischaemia in an isolated rabbit heart model. Cardiovasc. Res., 1987, 21, 293-298.
37. Lefer, A.M.; Campbell, B.; Scalia, R.; Lefer, D.J. Synergism between platelets and neutrophils in provoking cardiac dysfunction after ischemia and reperfusion: role of selectins. Circulation, 1998, 98, 1322-1328.
38. Heindl, B.; Zahler, S.; Welsch, U.; Becker, B.F. Disparate effects of adhesion and degranulation of platelets on myocardial and coronary function in postischaemic hearts. Cardiovasc. Res., 1998, 38, 383-394.
39. Seligmann, C.; Kupatt, C.; Becker, B.F.; Zahler, S.; Beblo, S. Adenosine endogenously released during early reperfusion mitigates postischemic myocardial dysfunction by inhibiting platelet adhesion. J. Cardiovasc. Pharmacol. 1998, 32, 156-163.
40. Flores, N.A.; Botchway, A.N.; Stavrou, B.M.; Sheridan, D.J. Cardiac electrophysiological effects of platelet-derived substances. Exp. Physiol., 1999, 84, 253-274.
41. Yang, B.C.; Virmani, R.; Nichols, W.W.; Mehta, J.L. Platelets protect against myocardial dysfunction and injury induced by ischemia and reperfusion in isolated rat hearts. Circ. Res., 1993, 72, 1181-1190.
42. Mullane, K.M.; McGiff, J.C. Platelet depletion and infarct size in an occlusion-reperfusion model of myocardial ischemia in anesthetized dogs. J. Cardiovasc. Pharmacol., 1985, 7, 733-738.
43. Barrabés, J.A.; Inserte, J.; Mirabet, M.; Quiroga, A.; Hernando, V.; Figueras, J.; Garcia-Dorado, D. Antagonism of P2Y12 or GPIIb/IIIa receptors reduces platelet-mediated myocardial injury after ischemia and reperfusion in isolated rat hearts. Thromb. Haemost., 2010, 104, 128-135.
44. Weig, H.J.; Bott-Flügel, L.; Städele, C.; Winter, K.; Schmidt, R.; Gawaz, M.; Laugwitz, K.L.; Seyfarth, M. Impaired platelet function reduces myocardial infarct size in Galphaq knock-out mice in vivo. J. Mol. Cell Cardiol., 2008, 44, 143-150.
45. Heusch, G.; Kleinbongard, P.; Böse, D.; Levkau, B.; Haude, M.; Schulz, R.; Erbel, R. Coronary microembolization: from bedside to bench and back to bedside. Circulation, 2009, 120, 1822-1836.
46. Gewirtz, H.; Sasken, H.; Steiner, M.; Most, A.S. Impaired arteriolar vasodilation induced by thrombosis of a coronary arterial stenosis. Am. J. Physiol., 1985, 249, H1154-1166.
47. Barrabés, J.A.; Garcia-Dorado, D.; Oliveras, J.; González, M.A.; Ruiz-Meana, M.; Solares, J.; Burillo, A.G.; Lidón, R.M.; Antolín, M.; Castell, J.; Soler-Soler, J. Intimal injury in a transiently occluded coronary artery increases myocardial necrosis: effect of aspirin. Pflugers Arch., 1996, 432, 663-670.
48. Mansaray, M.; Belcher, P.R.; Vergroesen, I.; Wright, Z.M.; Hynd, J.W.; Drake-Holland, A.J.; Noble, M.I. Downstream resistance effects of intracoronary thrombosis in the stenosed canine coronary artery. Cardiovasc. Res., 1999, 42, 193-200.
49. Folts, J.D.; Crowell, E.B.; Jr, Rowe, G.G. Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation, 1976, 54, 365-370.
50. Haerem, J.W. Platelet aggregates in intramyocardial vessels of patients dying suddenly and unexpectedly of coronary artery disease. Atherosclerosis, 1972, 15, 199-213.
51. Falk, E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation, 1985, 71, 699-708.
52. Davies, M.J.; Thomas, A.C.; Knapman, P.A.; Hangartner, J.R. Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death. Circulation, 1986, 73, 418-427.
53. Saber, R.S.; Edwards, W.D.; Bailey, K.R.; McGovern, T.W.; Schwartz, R.S.; Holmes, D.R.; Jr. Coronary embolization after balloon angioplasty or thrombolytic therapy: an autopsy study of 32 cases. J. Am. Coll. Cardiol., 1993, 22, 1283-1288.
54. Taylor, A.J.; Bobik, A.; Berndt, M.C.; Ramsay, D.; Jennings, G. Experimental rupture of atherosclerotic lesions increases distal vascular resistance: a limiting factor to the success of infarct angioplasty. Arterioscler. Thromb. Vasc. Biol., 2002, 22, 153-160.
55. Gawaz, M. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc. Res., 2004, 61, 498-511.
56. Massberg, S.; Enders, G.; Leiderer, R.; Eisenmenger, S.; Vestweber, D.; Krombach, F.; Messmer, K. Platelet-endothelial cell interactions during ischemia/reperfusion: the role of P-selectin. Blood, 1998, 92, 507-515.
57. Massberg, S.; Enders, G.; Matos, F.C.; Tomic, L.I.; Leiderer, R.; Eisenmenger, S.; Messmer, K.; Krombach, F. Fibrinogen deposition at the postischemic vessel wall promotes platelet adhesion during ischemia-reperfusion in vivo. Blood, 1999, 94, 3829-3838.
58. Cooper, D.; Russell, J.; Chitman, K.D.; Williams, M.C.; Wolf, R.E.; Granger, D.N. Leukocyte dependence of platelet adhesion in postcapillary venules. Am. J. Physiol. Heart Circ. Physiol., 2004, 286, H1895-H1900.
59. Takaya, N.; Katoh, Y.; Iwabuchi, K.; Hayashi, I.; Konishi, H.; Itoh, S.; Okumura, K.; Ra C.; Nagaoka, I.; Daida, H. Platelets activated by collagen through the immunoreceptor tyrosine-based activation motif in the Fc receptor gamma-chain play a pivotal role in the development of myocardial ischemia-reperfusion injury. J. Mol. Cell Cardiol., 2005, 39, 856-864.
60. Mullane, K.M.; Fornabaio, D. Thromboxane synthetase inhibitors reduce infarct size by a platelet-dependent, aspirin-sensitive mechanism. Circ. Res., 1988, 62, 668-678.
61. Mirabet, M.; Barrabés, J.A.; Quiroga, A.; Garcia-Dorado, D. Platelet pro-aggregatory effects of CD40L monoclonal antibody. Mol. Immunol., 2008, 45, 937-944 [erratum in: Mol Immunol. 2008, 45, 2721].
62. Mirabet, M.; Garcia-Dorado, D.; Ruiz-Meana, M.; Barrabés, J.A.; Soler-Soler, J. Thrombin increases cardiomyocyte acute cell death after ischemia and reperfusion. J. Mol. Cell Cardiol., 2005, 39, 277-283.
63. Svilaas, T.; Vlaar, P.J.; van der Horst, I.C.; Diercks, G.F.; de Smet, B.J.; van den Heuvel, A.F.; Anthonio, R.L.; Jessurun, G.A.; Tan, E.S.; Suurmeijer, A.J.; Zijlstra, F. Thrombus aspiration during primary percutaneous coronary intervention. N. Engl. J. Med., 2008, 358, 557-567.
64. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet, 1988, 2, 349-360.
65. Chen, Z.M.; Jiang, L.X.; Chen, Y.P.; Xie, J.X.; Pan, H.C.; Peto, R.; Collins, R.; Liu, L.S.; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet, 2005, 366, 1607-1621.
66. Storey, R.F.; Judge, H.M.; Wilcox, R.G.; Heptinstall, S. Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin. Thromb. Haemost., 2002, 88, 488-494.
67. Heitzer, T.; Rudolph, V.; Schwedhelm, E.; Karstens, M.; Sydow, K.; Ortak, M.; Tschentscher, P.; Meinertz, T.; Böger, R.; Baldus, S. Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: evidence for antioxidant and antiinflammatory effects. Arterioscler. Thromb. Vasc. Biol., 2006, 26, 1648-1652.
68. Scirica, B.M.; Sabatine, M.S.; Morrow, D.A.; Gibson, C.M.; Murphy, S.A.; Wiviott, S.D.; Giugliano, R.P.; McCabe, C.H.; Cannon, C.P.; Braunwald, E. The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study. J. Am. Coll. Cardiol., 2006, 48, 37-42.
69. Lev, E.I.; Kornowski, R.; Vaknin-Assa, H.; Brosh, D.; Fuchs, S.; Battler, A.; Assali, A. Effect of clopidogrel pretreatment on angiographic and clinical outcomes in patients undergoing primary percutaneous coronary intervention for ST-elevation acute myocardial infarction. Am. J. Cardiol., 2008, 101, 435-439.
70. Harrington, R.A.; Stone, G.W.; McNulty, S.; White, H.D.; Lincoff, A.M.; Gibson, C.M.; Pollack, C.V.; Jr, Montalescot, G.; Mahaffey, K.W.; Kleiman, N.S.; Goodman, S.G.; Amine, M.; Angiolillo, D.J.; Becker, R.C.; Chew, D.P.; French, W.J.; Leisch, F.; Parikh, K.H.; Skerjanec, S.; Bhatt, D.L. Platelet inhibition with cangrelor in patients undergoing PCI. N. Engl. J. Med., 2009, 361, 2318-2329.
71. Wang, K.; Zhou, X.; Zhou, Z.; Tarakji, K.; Carneiro, M.; Penn, M.S.; Murray, D.; Klein, A.; Humphries, R.G.; Turner, J.; Thomas, J.D.; Topol, E.J.; Lincoff, A.M. Blockade of the platelet P2Y12 receptor by AR-C69931MX sustains coronary artery recanalization and improves the myocardial tissue perfusion in a canine thrombosis model. Arterioscler. Thromb. Vasc. Biol., 2003, 23, 357-362.
72. Greenbaum, A.B.; Ohman, E.M.; Gibson, C.M.; Borzak, S.; Stebbins, A.L.; Lu, M.; Le May, M.R.; Stankowski, J.E.; Emanuelsson, H.; Weaver, W.D. Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEPAMI) angiographic trial. Am. Heart J., 2007, 154, 702-709.
73. Wiviott, S.D.; Braunwald, E.; McCabe, C.H.; Montalescot, G.; Ruzyllo, W.; Gottlieb, S.; Neumann, F.J.; Ardissino, D.; De Servi, S.; Murphy, S.A.; Riesmeyer, J.; Weerakkody, G.; Gibson, C.M.; Antman, E.M. for the TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med., 2007, 357, 2001-2015.
74. Wallentin, L.; Becker, R.C.; Budaj, A.; Cannon, C.P.; Emanuelsson, H.; Held, C.; Horrow, J.; Husted, S.; James, S.; Katus, H.; Mahaffey, K.W.; Scirica, B.M.; Skene, A.; Steg, P.G.; Storey, R.F.; Harrington, R.A.; for the PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med., 2009, 361, 1045-1057.
75. Marzilli, M.; Sambuceti, G.; Testa, R.; Fedele, S. Platelet glycoprotein IIb/IIIa receptor blockade and coronary resistance in unstable angina. J. Am. Coll. Cardiol., 2002, 40, 2102-2109.
76. Neumann, F.J.; Blasini, R.; Schmitt, C.; Alt, E.; Dirschinger, J.; Gawaz, M.; Kastrati, A.; Schömig, A. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation, 1998, 98, 2695-2701.
77. Kingma, J.G.; Jr, Plante, S.; Bogaty, P. Platelet GPIIb/IIIa receptor blockade reduces infarct size in a canine model of ischemiareperfusion. J. Am. Coll. Cardiol., 2000, 36, 2317-2324.
78. Kunichika, H.; Ben-Yehuda, O.; Lafitte, S.; Kunichika, N.; Peters, B.; DeMaria, A.N. Effects of glycoprotein IIb/IIIa inhibition on microvascular flow after coronary reperfusion: a quantitative myocardial contrast echocardiography study. J. Am. Coll. Cardiol., 2004, 43, 276-283.
79. Neumann, F.J.; Zohlnhöfer, D.; Fakhoury, L.; Ott, I.; Gawaz, M.; Schömig, A. Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction. J. Am. Coll. Cardiol., 1999, 34, 1420-1426.
80. Kupatt, C.; Habazettl, H.; Hanusch, P.; Wichels, R.; Hahnel, D.; Becker, B.F.; Boekstegers, P. c7E3Fab reduces postischemic leukocyte-thrombocyte interaction mediated by fibrinogen: implica tions for myocardial reperfusion injury. Arterioscler. Thromb. Vasc. Biol., 2000, 20, 2226-2232.
81. Tam, S.H.; Sassoli, P.M.; Jordan, R.E.; Nakada, M.T. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and avβ3 integrins. Circulation, 1998, 98, 1085-1091.
82. Sakuma, T.; Sari, I.; Goodman, C.N.; Lindner, J.R.; Klibanov, A.L.; Kaul, S. Simultaneous integrin avβ3 and glycoprotein IIb/IIIa inhibition causes reduction in infarct size in a model of acute coronary thrombosis and primary angioplasty. Cardiovasc. Res., 2005, 66, 552-561.
83. Antman, E.M.; Giugliano, R.P.; Gibson, C.M.; McCabe, C.H.; Coussement, P.; Kleiman, N.S.; Vahanian, A.; Adgey, A.A.; Menown, I.; Rupprecht, H.J.; Van der Wieken, R.; Ducas, J.; Scherer, J.; Anderson, K.; Van de Werf, F.; Braunwald, E. Abciximab facilitates the rate and extent of thrombolysis: results of the Thrombolysis In Myocardial Infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation, 1999, 99, 2720-2732.
84. Van't Hof, A.W.; Ten Berg, J.; Heestermans, T.; Dill, T.; Funck, R.C.; van Werkum, W.; Dambrink, J.H.; Suryapranata, H.; van Houwelingen, G.; Ottervanger, J.P.; Stella, P.; Giannitsis, E.; Hamm, C. Ongoing Tirofiban In Myocardial infarction Evaluation (On-TIME) 2 study group. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomized controlled trial. Lancet, 2008, 372, 537-546.
85. De Luca, G.; Marino, P. Advances in antithrombotic therapy as adjunct to reperfusion therapies for ST-segment elevation myocardial infarction. Thromb. Haemost., 2008, 100, 184-195.
86. Valgimigli, M.; Campo, G.; Percoco, G.; Bolognese, L.; Vassanelli, C.; Colangelo, S.; de Cesare, N.; Rodriguez, A.E.; Ferrario, M.; Moreno, R.; Piva, T.; Sheiban, I.; Pasquetto, G.; Prati, F.; Nazzaro, M.S.; Parrinello, G.; Ferrari, R. Multicentre Evaluation of Single High-Dose Bolus Tirofiban vs Abciximab With Sirolimus-Eluting Stent or Bare Metal Stent in Acute Myocardial Infarction Study (MULTISTRATEGY) Investigators. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. JAMA, 2008, 299, 1788-1799.
87. Gurm, H.S.; Tamhane, U.; Meier, P.; Grossman, P.M.; Chetcuti, S.; Bates, E.R. A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials. Circ. Cardiovasc. Interv., 2009, 2, 230-236.
88. De Luca, G.; Gibson, C.M.; Bellandi, F.; Murphy, S.; Maioli, M.; Noc, M.; Zeymer, U.; Dudek, D.; Arntz, H.R.; Zorman, S.; Gabriel, H.M.; Emre, A.; Cutlip, D.; Biondi-Zoccai, G.; Rakowski, T.; Gyongyosi, M.; Marino, P.; Huber, K.; van't Hof, A.W. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data meta-analysis. Heart, 2008, 94, 1548-1558.
89. Ellis, S.G.; Tendera, M.; de Belder, M.A.; van Boven, A.J.; Widimsky, P.; Janssens, L.; Andersen, H.R.; Betriu, A.; Savonitto, S.; Adamus, J.; Peruga, J.Z.; Kosmider, M.; Katz, O.; Neunteufl, T.; Jorgova, J.; Dorobantu, M.; Grinfeld, L.; Armstrong, P.; Brodie, B.R.; Herrmann, H.C.; Montalescot, G.; Neumann, F.J.; Effron, M.B.; Barnathan, E.S.; Topol, E.J.; FINESSE Investigators. Facilitated PCI in patients with ST-elevation myocardial infarction. N. Engl. J. Med., 2008, 358, 2205-2217.
90. Mehilli, J.; Kastrati, A.; Schulz, S.; Früngel, S.; Nekolla, S.G.; Moshage, W.; Dotzer, F.; Huber, K.; Pache, J.; Dirschinger, J.; Seyfarth, M.; Martinoff, S.; Schwaiger, M.; Schömig, A.; Bavarian, Reperfusion Alternatives Evaluation-3 (BRAVE-3) Study Investigators. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation, 2009, 119, 1933-1940.
91. Thiele, H.; Schindler, K.; Friedenberger, J.; Eitel, I.; Fürnau, G.; Grebe, E.; Erbs, S.; Linke, A.; Möbius-Winkler, S.; Kivelitz, D.; Schuler, G. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation, 2008, 118, 49-57.
92. Wang, K.; Zhou, X.; Zhou, Z.; Tarakji, K.; Qin, J.X.; Sitges, M.; Shiota, T.; Forudi, F.; Schaub, R.G.; Kumar, A.; Penn, M.S.; Topol, E.J.; Lincoff, A.M. Recombinant soluble P-selectin glycoprotein ligand-Ig (rPSGL-Ig) attenuates infarct size and myeloperoxidase activity in a canine model of ischemia-reperfusion. Thromb. Haemost., 2002, 88, 149-154.
93. Hansen, A.; Kumar, A.; Wolf, D.; Frankenbergerova, K.; Filusch, A.; Gross, M.L.; Mueller, S.; Katus, H.; Kuecherer, H. Evaluation of cardioprotective effects of recombinant soluble P-selectin glycoprotein ligand-immunoglobulin in myocardial ischemia-reperfusion injury by real-time myocardial contrast echocardiography. J. Am. Coll Cardiol., 2004, 44, 887-891.
94. Mertens, P.; Maes, A.; Nuyts, J.; Belmans, A.; Desmet, W.; Esplugas, E.; Charlier, F.; Figueras, J.; Sambuceti, G.; Schwaiger, M.; Mortelmans, L.; Van de Werf, F.; PSALM investigators. Recombinant P-selectin glycoprotein ligand-immunoglobulin, a P-selectin antagonist, as an adjunct to thrombolysis in acute myocardial infarction: the P-Selectin Antagonist Limiting Myonecrosis (PSALM) trial. Am. Heart J., 2006, 152, 125.e1-e8.
95. Sezer, M.; Cimen, A.; Aslanger, E.; Elitok, A.; Umman, B.; Buǧra, Z.; Yormaz, E.; Türkmen, C.; Adalet, I.S.; Nişanci, Y.; Umman, S. Effect of intracoronary streptokinase administered immediately after primary percutaneous coronary intervention on long-term left ventricular infarct size, volumes, and function. J. Am. Coll. Cardiol., 2009, 54, 1065-1071.
96. Ross, A.M.; Gibbons, R.J.; Stone, G.W.; Kloner, R.A.; Alexander, R.W. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J. Am. Coll. Cardiol., 2005, 45, 1775-1780.
97. Ishii, H.; Ichimiya, S.; Kanashiro, M.; Amano, T.; Imai, K.; Murohara, T.; Matsubara, T. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segmentelevation myocardial infarction. Circulation, 2005, 112, 1284-1288.
98. Amit, G.; Cafri, C.; Yaroslavtsev, S.; Fuchs, S.; Paltiel, O.; Abu-Ful, A.; Weinstein, J.M.; Wolak, A.; Ilia, R.; Zahger, D. Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction: a randomized, double-blind, placebo-controlled clinical trial. Am. Heart J., 2006, 152, 887.e9-14.
99. Kitakaze, M.; Asakura, M.; Kim, J.; Shintani, Y.; Asanuma, H.; Hamasaki, T.; Seguchi, O.; Myoishi, M.; Minamino, T.; Ohara, T.; Nagai, Y.; Nanto, S.; Watanabe, K.; Fukuzawa, S.; Hirayama, A.; Nakamura, N.; Kimura, K.; Fujii, K.; Ishihara, M.; Saito, Y.; Tomoike, H.; Kitamura, S. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet, 2007, 370, 1483-1493 [Erratum in: Lancet, 2008, 370, 2102].
100. Minamino, T.; Kitakaze, M.; Asanuma, H.; Tomiyama, Y.; Shiraga, M.; Sato, H.; Ueda, Y.; Funaya, H.; Kuzuya, T.; Matsuzawa, Y.; Hori, M. Endogenous adenosine inhibits P-selectin-dependent formation of coronary thromboemboli during hypoperfusion in dogs. J. Clin. Invest., 1998, 101, 1643-1653.
101. Marzilli, M.; Orsini, E.; Marraccini, P.; Testa, R. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation, 2000, 101, 2154-2159.
102. Kloner, R.A.; Forman, M.B.; Gibbons, R.J.; Ross, A.M.; Alexander, R.W.; Stone, G.W. Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. Eur. Heart J., 2006, 27, 2400-2405.
103. Zafar, M.U.; Vilahur, G.; Choi, B.G.; Ibanez, B.; Viles-Gonzalez, J.F.; Salas, E.; Badimon, J.J. A novel anti-ischemic nitric oxide donor (LA419) reduces thrombogenesis in healthy human subjects. J. Thromb. Haemost., 2007, 5, 1195-1200.
104. Iwakura, K.; Ito, H.; Kawano, S.; Okamura, A.; Kurotobi, T.; Date, M.; Inoue, K.; Fujii, K. Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction. Eur. Heart J., 2006, 27, 534-539.
105. Hausenloy, D.J.; Yellon, D.M. Remote ischaemic preconditioning: underlying mechanisms and clinical application. Cardiovasc. Res., 2008, 79, 377-386.
106. Ruiz-Meana, M.; García-Dorado, D. Pathophysiology of ischemiareperfusion injury: new therapeutic options for acute myocardial infarction. Rev. Esp. Cardiol., 2009, 62,199-209.
107. Inserte, J.; Barrabés, J.A.; Hernando, V.; Garcia-Dorado, D. Orphan targets for reperfusion injury. Cardiovasc. Res., 2009, 83, 169-178.